CEO INTERVIEW: Sipping Nanotech: Clene's Revolutionary Drink to Combat ALS and MS

In this revelatory episode, Carmel Fisher interviews Mr Rob Etherington CEO of Clene, Inc., listed on NASDAQ as CLNN.Clene, Inc., a clinical-stage biopharmaceutical company is dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function.There is no-one else who is theorizing orally-ingestive nanotherapeutics that target cellular energy impairments, common to many diseases, including ALS (Amyotrophic lateral sclerosis) and MS (Multiple Sclerosis)!For more information, visit:Clene, Inc. InvestorsALS: https://www.cdc.gov/als/WhatisAmyotrophiclateralsclerosis.htmlMS: https://www.who.int/news-room/fact-sheets/detail/multiple-sclerosisDisclaimer:The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned.The content of this podcast does not constitute investment, legal, or tax advice. Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions.Past performance is not indicative of future results. The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements.Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.Always do your own due diligence and invest responsibly.